Gestational diabetes mellitus (GDM) is becoming increasingly common worldwide, especially in regions undergoing rapid lifestyle and dietary transitions. Traditionally, GDM has been viewed through the lens of short-term maternal and neonatal complications such as macrosomia, neonatal hypoglycaemia, and increased Caesarean birth rates. However, emerging research indicates that its impact may extend far beyond delivery, potentially influencing the cognitive and behavioural trajectory of exposed children.

A growing body of evidence, including recent large-scale population studies, now suggests a meaningful association between maternal hyperglycaemia during pregnancy and increased risk of autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) in offspring.

Background
The developing fetal brain is highly sensitive to metabolic signals during pregnancy. Glucose freely crosses the placenta, and chronic exposure to elevated glucose levels may alter neuronal growth, synapse formation, and gene expression. Over the last decade, researchers have explored whether dysregulated maternal metabolism including insulin resistance, inflammation, and oxidative stress, may influence neurodevelopmental outcomes. While initial studies offered mixed results, recent high-quality data from diverse populations provide clearer evidence that prenatal metabolic disturbances are linked to later neurodevelopmental risks.

Key Findings:

• A large meta‐analysis of 48 observational studies covering over 9 million pregnancies found that mothers with Gestational Diabetes Mellitus (GDM) scored on average 2.5 points lower (out of 30) on the Montreal Cognitive Assessment compared with non‐GDM mothers.
• For children born to mothers with GDM, the average reduction in IQ was about 3.92 points, and their verbal crystallised intelligence was ~3.18 points lower than peers.
• The children’s risk of diagnosed neurodevelopmental disorders was substantially increased: ~36 % higher risk of Attention Deficit Hyperactivity Disorder (ADHD), and ~56 % higher risk of Autism Spectrum Disorder (ASD) when exposed to maternal GDM.
• Approximate global prevalence: GDM affects about 14 % of pregnancies worldwide, and its incidence is rising among older mothers, obese mothers, non-White ethnicities and those with family history of diabetes.

How Might Gestational Diabetes Influence the Developing Brain?
Although definitive mechanisms are still under investigation, several plausible pathways have emerged from experimental and clinical research:

• Fetal hyperinsulinemia due to maternal hyperglycemia may disrupt normal neuronal energy metabolism.
• Chronic low-grade inflammation during pregnancy may alter neurotransmitter pathways and synaptic signalling.
• Oxidative and metabolic stress in the placenta may impair the timing and patterning of brain development.
• Hormonal changes, including elevated insulin, leptin and cortisol, may interfere with neuronal maturation and stress-response circuitry.
• Epigenetic changes triggered during pregnancy may have lifelong influence on brain development and behaviour.
These mechanisms collectively suggest that GDM may not only affect fetal growth and metabolism but could also influence neural networks involved in cognition, behaviour, and executive functioning.

Why This Matters

• Children born to mothers with gestational diabetes had lower levels of a protein called brain-derived neurotrophic factor, or BDNF. This protein supports the growth and repair of brain cells and is vital for learning and memory. Reduced levels could point to slower or less resilient brain development, though the precise effect is still uncertain
• Studies suggest that the metabolic environment during pregnancy including glucose levels, insulin, possibly inflammation or hypoxia, may influence in-utero brain development and later developmental outcomes in childhood.
• Although causation is not confirmed, the findings argue for heightened vigilance: better screening, tighter glycaemic control, and follow-up for children exposed to GDM.
• From a public health standpoint, with GDM becoming more common, the downstream neurocognitive burden may rise making prevention, management and awareness all the more urgent.

Implications for Practice & Policy

• For clinicians: Consider GDM not only as a obstetric/metabolic risk but also a risk factor for offspring neurodevelopmental outcome.
• For pregnant women: Emphasise early screening (typically around 24–28 weeks), lifestyle modifications (diet, physical activity), and if necessary, medical management of glucose.
• For pediatrics/early-childhood follow-up: Recognise that children born after a GDM pregnancy may warrant developmental monitoring (language/verbal skills, attention, behaviour) even if overt disorders are not present.
• For policy & systems: Strengthen preconception care and maternal metabolic health programmes, particularly in high-risk groups (obesity, older age, family history) to reduce GDM incidence.
• For research: Needs remain for long-term cohort follow-up (children into adolescence and adulthood), mechanistic studies (how exactly maternal hyperglycaemia affects neuro-development) and interventions to mitigate risk.

      GEMS Takeaway

This evolving evidence challenges us to broaden our understanding of gestational diabetes beyond birth outcomes. Optimizing metabolic health before and during pregnancy may serve as a long-term investment in both maternal well-being and future child development.
As science progresses, early life metabolic environments including intrauterine glucose exposure, may become central considerations in neurodevelopmental disease prevention.

Read More